CCDC183-AS1: A Potential Drug Target and Biomarker (G100131193)

Target Name: CCDC183-AS1

NCBI ID: G100131193

CCDC183-AS1

Other Name(s): KIAA1984-AS1 | RP11-216L13.8 | CCDC183 antisense RNA 1

CCDC183-AS1: A Potential Drug Target and Biomarker

CDC183-AS1, also known as CSF1, is a protein that is expressed in the cerebellum, which is the part of the brain responsible for motor coordination and balance. It has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

CDC183-AS1: Structure and Function

CDC183-AS1 is a transmembrane protein that is expressed in the cerebellum and is involved in the development and maintenance of normal cerebellum structure and function. It is a member of the Tetraspan gene family, which includes proteins that are involved in the regulation of cell-cell interactions, including those between cells and the extracellular matrix (ECM).

CDC183-AS1 is involved in the development and maintenance of the normal structure of the cerebellum, including the development of new neurons and the maintenance of the integrity of existing neurons. It is also involved in the regulation of the movement of neurons, which is critical for normal motor function.

CDC183-AS1: Potential Drug Target

CDC183-AS1 has been identified as a potential drug target for various neurological and psychiatric disorders due to its involvement in the regulation of normal brain function. One of the main targets of CDC183-AS1 is the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In Alzheimer's disease, the accumulation of toxic beta-amyloid peptides is thought to contribute to the destruction of brain cells and the development of the disease. CDC183-AS1 has been shown to regulate the production of beta-amyloid peptides and has been shown to be involved in the protective effects against beta-amyloid peptide-induced neurotoxicity.

In addition to its potential role in the development of neurodegenerative disorders, CDC183-AS1 may also be a useful biomarker for these disorders. The loss of normal cerebellum structure and function is a common feature of neurodegenerative disorders, and changes in the expression of CDC183-AS1 may provide insight into the severity and progression of these disorders.

CDC183-AS1: Potential Biomarker

CDC183-AS1 has also been identified as a potential biomarker for various neurological and psychiatric disorders. The loss of normal cerebellum structure and function is a common feature of many neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

CDC183-AS1 may be used as a biomarker for these disorders by measuring the expression of its gene in the cerebellum. The expression of CDC183-AS1 may be affected by the presence of various neurological and psychiatric disorders, and changes in its expression may provide insight into the severity and progression of these disorders.

Conclusion

In conclusion, CDC183-AS1 is a protein that is expressed in the cerebellum and is involved in the development and maintenance of normal cerebellum structure and function. It has been identified as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease and Parkinson's disease. It may also be a useful biomarker for these disorders by measuring the expression of its gene in the cerebellum. Further research is needed to fully understand the role of CDC183-AS1 in the development and treatment of neurodegenerative disorders.

Protein Name: CCDC183 Antisense RNA 1

The "CCDC183-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC183-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets